A 2006 Phase I trial of CJC-1295 reported no serious adverse events across a small number of subjects, but it was a safety study, not an outcomes trial, and there are no large trials showing it does what enthusiasts hope
For BPC-157 the peptide that received the most attention and the first vote of the two-day meeting the evidentiary picture was the most developed of the group, which is not saying much
DIETARY REGULATORS OF GSTP1 EXPRESSION Since progressive GSTP1 hypermethylation is a hallmark biomarker but potentially also a driver of prostate cancer progression, various research teams were looking for dietary intervention to lower the methylation burden of GSTP1 gene promoter
Lets explore the science and benefits behind these innovative approaches
Sahu N, Jain P, Sahu D, Kaur K, Nagori K, Ajazuddin
Do not change the dose of Hizentra without talking with your healthcare provider